Thuja Capital exits NightBalance to Philips

 Thuja Capital exits NightBalance to Philips

8 May, 2018, Utrecht, The Netherlands – Thuja Capital announced it has sold its shareholding in NightBalance B.V. (The Hague, Netherlands) to Royal Philips (NYSE: PHG, AEX: PHIA).

Philips has agreed to acquire all outstanding shares of NightBalance, a digital health scale-up company that has developed an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring.

NightBalance obtains reimbursement in the Netherlands for its innovative sleep apnea therapy

NightBalance obtains reimbursement in the Netherlands for its innovative sleep apnea therapy

22 December 2017, The Hague, The Netherlands – NightBalance, a leader in innovative obstructive sleep apnea (OSA) therapies, today announced that the Dutch National Health Care Institute (ZIN) issued a positive recommendation to include its sleep apnea therapy for reimbursement. The Dutch Ministry of Health, Welfare and Sport will formally approve inclusion of the SPT® following ZIN’s recommendation.

Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials

Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials

28 November 2017, Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. 

MILabs’ VECTor6 with groundbreaking PET performance awarded Innovation of the Year at the WMIC 2018

MILabs’ VECTor6 with groundbreaking PET performance awarded Innovation of the Year at the WMIC 2018

15 September 2018, Utrecht, The Netherlands – MILabs is pleased to announce that its new VECTor6 with Broadband Photon Tomography technique has received the Commercial Innovation Award at the World Molecular Imaging Congress (WMIC) in Seattle September 12th-15th, 2018.

Cristal Therapeutics initiates phase 2 clinical trial with CriPec docetaxel in ovarian cancer

Cristal Therapeutics initiates phase 2 clinical trial with CriPec docetaxel in ovarian cancer

25 October 2018 , Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer.

Cristal Therapeutics appoints Dr. Axel Mescheder as CEO and CMO

Cristal Therapeutics appoints Dr. Axel Mescheder as CEO and CMO

2 November 2018, Maastricht, The Netherlands – Cristal Therapeutics has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO).